|
|
 |
November 29, 2007 |
Now Available: Download the podcast of Dr. Epstein's video presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Hot Topics in Osteoporosis
Sol Epstein presents Hot Topics in Osteoporosis: Osteonecrosis of the
Jaw, Bisphosphonate 'Drug Holidays,'
and Male Osteoporosis...
CME News: New Method Provides Quick Estimate of 5-Year Hip Fracture Risk
A new algorithm based on 11 clinical factors can predict 5-year risk for hip fracture in postmenopausal women...
ACR 2007: ACR Update on Joint Replacement
Total joint replacement has reduced pain and disability in elderly patients with arthritis. The procedure is cost-effective even for high-risk patients, but it is associated with higher risk for cardiac complications if both joints are replaced during the same procedure, and it might be chosen by more African-American patients if finances were less of an issue...
Bones: Osteoporosis Also Contributes to High-Trauma Fractures
Physicians should evaluate older patients with high-trauma nonspine fractures for osteoporosis...
BioPharm Business: Osiris Announces Clinically and Statistically Significant 1-Year Data From Phase I/II Trial of Chondrogen; OA Knee Patients Receive Single Injection of Adult Stem Cells Into Knee
Osiris Therapeutics, Inc, a leading stem cell therapeutic company, announced positive 1-year interim results in the evaluation of Chondrogen, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and formulated for direct injection into the knee...
BioPharm Business: MedImmune Initiates First Phase I Trial of an Anti-GM-CSFR Monoclonal Antibody in Patients With RA
MedImmune, Inc announced that dosing of patients has begun in the first phase I clinical trial of CAM-3001, a fully human monoclonal antibody targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor. The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with rheumatoid arthritis...